DPA Foundation



The Digital Pathology Association Foundation (DPAF), a 501(c)(3) organization, was established in 2016 to raise philanthropic support to help realize the promise of digital pathology. 


The DPAF's mission to accelerate adoption of digital pathology to improve patient outcomes globally, is realized through the support of individuals and institutions whose philanthropic mission aligns with ours. 


The Foundation is seeking institutional and individual donations. Any amount will assist the DPAF in achieving its mission and is greatly appreciated. To learn more about the Foundation including opportunities to get involved, please contact: foundation@digitalpathologyassociation.org.


The Foundation’s current focus is investing in research to demonstrate the impact of digital pathology for both patients and providers. Alongside the DPA’s advocacy and coordination of industry efforts, the Foundation’s work will help pave the way for broad public and private investment in the digital transformation of pathology in America and around the world.




The Foundation underpins the DPA by providing funding and the mechanism for conducting essential projects, including the “Outcomes Study” which will document the impacts of digital pathology for patients and providers across a wide range of practice settings and communities. The methodology will be synthesizing existing studies which have already been published, and institutional data that has been made public and conducting new analysis of institutional data that has not been broadly shared before.


With the data collected, the study will assess the impacts, experiences, and challenges associated with implementing digital pathology, with a focus in two key areas:


  • Patient Outcomes: diagnosis speed and accuracy, personalized medicine, treatment outcomes
  • Provider Outcomes: efficiency and productivity of Pathology, process improvement in physician and institutional collaboration


The projects ultimate goal is to bring the benefits of Digital Pathology to every possible community and individual, its timeline is estimated to be over a period of 2-3 years.






Michael Rivers

Vice President & General Manager, Mountain View
Roche Tissue Diagnostics


John Wellbank

Digital Pathology Consultant





Lewis Hassell, MD

Director of Anatomic Pathology

University of Oklahoma Health Sciences Center



Keith Wharton, MD, PhD, FCAP

Global Medical Affairs Lead

Roche Tissue Diagnostics




Chhavi Chauhan, PhD, ELS

Director of Scientific Outreach

American Society for Investigative Pathology



Chris Garcia, MD

Computational Pathologist

Mayo Clinic




Michael Isaacs

Director of Information System, Pathology & Immunology

Washington University School of Medicine



Jennifer Samboy

Digital Transformation Leader

Philips Digital & Computational Pathology




Michael Valante

Global Healthcare Business Lead

Chief Technology Officer

                               Dell Technologies